Previous 10 | Next 10 |
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360 ® CDx, a liquid biopsy test for tumor mutation profiling, also known as compr...
Oral Presentation to Feature Key Findings from Next-Generation Guardant SHIELD ™ Assay for Early-Stage Multi-Cancer Screening Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data from its broad portfoli...
Guardant Health (NASDAQ: GH) shares were up 4.6% at Tuesday's close after the company announced its Guardant360 TissueNext test will be included among the diagnostic tests that at least one Medicare insurance service provider covers. It's complicated; here's the simple and short...
Guardant Health (GH +5.1%) is set to close higher for the first time in four sessions on Tuesday after the precision oncology company announced a favorable decision on Medicare coverage for its Guardant360 TissueNext test. Widening the public access to the test, Palmetto GBA, a Medicare admin...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for Guardant360 TissueNext™ under the existing local coverage ...
Guardant Health (NASDAQ: GH) shareholders had a fine Thursday, as the cancer-diagnostics company's stock saw a 10% pop. This was thanks to its latest quarterly earnings report, which delivered a pair of extremely pleasant upside surprises. Guardant Health's Q4 and full-year 2021...
The following slide deck was published by Guardant Health, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Guardant Health, Inc. 2021 Q4 - Results - Earnings Call Presentation
Guardant Health, Inc. (GH) Q4 2021 Earnings Conference Call February 23, 2022 16:30 ET Company Participants Carrie Mendivil - Investor Relations Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Partici...
Guardant Health press release (NASDAQ:GH): Q4 Non-GAAP EPS of -$0.69 beats by $0.39. Revenue of $108.11M (+38.0% Y/Y) beats by $9.39M. Adjusted EBITDA loss was $64.6 million for the fourth quarter of 2021, as compared to a $29.7 million loss Y/Y. Guardant Health expects full year 2022 revenue...
Q4 clinical and biopharma volumes up 48% and 36% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported fin...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...